SAN JOSE, Calif. and ZURICH, Switzerland, Oct. 19, 2021 (GLOBE NEWSWIRE) — BrightInsight, Inc., provider of the world’s leading platform for biopharmaceutical and medtech regulated digital health solutions, today announced that Meinhard F. Schmidt joined the BrightInsight Advisory Board. Schmidt is the latest healthcare and technology luminary to join this group of 10 advisors working with BrightInsight’s leadership team to advance the company’s vision to transform patient outcomes at scale. world through the power of digital technology.
Mr. Schmidt joins BrightInsight’s advisory board as the company continues its rapid growth trajectory that includes launching digital health solutions in the U.S. and internationally with leading biopharmaceutical clients including AstraZeneca, CSL Behring , Novo Nordisk and Roche, doubling the staff and tripling its valuation. following a $101 million Series C funding round earlier this year led by General Catalyst.
“Meinhard Schmidt has been a friend and unofficial advisor to BrightInsight, and we are honored to have him officially join our advisory board. new products and services to meet growing demand for our regulated digital health platform,” said Kal Patel, MD, CEO and Co-Founder. “As we expand our global footprint and product offerings, the experience and network of Meinhard will help accelerate our growth in all areas of the business.”
Mr. Schmidt is an accomplished executive and consultant with more than 25 years of global experience in diagnostics, biotechnology, medical technology and digital health, leading transformational change for blue chips as well as start-ups. He has worked in Germany, the Netherlands, the United States, Canada, the United Kingdom, France, Ireland, Sweden, Austria and Switzerland. He currently sits on several corporate boards, consults with life science organizations to improve innovation, industrialization, commercialization and digitization processes; and advises private equity and venture capital firms to identify global candidates for investment and acquisition. Mr. Schmidt spent ten years at Roche Diagnostics where he held global leadership positions in diabetes care, laboratories and PoC diagnostics. As Executive Vice President of the Straumann Institute/Switzerland and CEO of their Digital Dentistry Unit, he was responsible for the global digitalization of the dental industry.
“I have been impressed with Dr. Kal Patel and his team since inception of BrightInsight. They clearly articulated their vision and then expertly executed their strategy to enable biopharmaceutical and medtech companies to build, scale and sustain regulated digital health products,” said Meinhard F. Schmidt. “I look forward to working closely with the team to expand BrightInsight’s global leadership position.”
About the BrightInsight Advisory Board
The BrightInsight Advisory Board includes some of the world’s most successful thought leaders in health and technology, including Mark T. Bertolini, Donald Jones, Kothandaraman Sridharan, Jeffrey Leiden, MD, Ph.D., Diana McKenzie, Kim Powell, Brent Saunders, Jagjot (JJ) Singh, Bradley Stock and Hemant Taneja.
About BrightInsight, Inc.
BrightInsight provides the world’s leading platform for biopharmaceutical and medical regulated digital health solutions. When speed matters, we help companies get regulated digital health offerings to market faster in all therapeutic areas, including apps, algorithms, medical devices, connected handset products, diagnostics and software as medical devices (SaMD). BrightInsight replaces the need for long and complex “build from scratch” implementations by offering configurable software modules and a proven platform built under a quality management system to support global security requirements, privacy and regulation. When building digital health products on the BrightInsight platform, compliance is future-proofed as intended usage changes in scale from geography to geography.
For more information, visit BrightInsight website, Blog, Twitter, and LinkedIn pages.
BrightInsight and the BrightInsight logo are trademarks of BrightInsight, Inc. Other company and product names are for identification purposes only and may be trademarks of their respective owners.
Media & Press
SVP, Marketing, BrightInsight
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e45974d2-ca80-43e5-9202-5b7a8d8e1345